Business Wire

CA-QUANERGY-SYSTEMS

26.9.2018 16:11:02 CEST | Business Wire | Press release

Share
Quanergy Announces Availability of Power Over Ethernet for M8 LiDAR Sensor

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced the availability of its M8 LiDAR sensor with Power over Ethernet (PoE+). This new connector interface, designed specifically for the security market, allows the sensor to be easily installed and integrated with new or existing security systems, without costly custom wiring to power the LiDAR sensor.

Surveillance systems leverage PoE to transmit power and data across the sensor and system. The IEEE 802.3at (PoE+) specification provides more power to PoE-powered devices and allows for a broader range of devices to be easily integrated into a network via standard Ethernet cable. The release of the M8 with PoE+ allows for a simpler, more flexible installation of LiDAR-based security systems. Its plug-and-play usability permits customers to make use of their existing security infrastructure when upgrading to a LiDAR-based security solution, leading to significant savings in implementation cost and time.

The M8 sensor’s long range and 360 degree field of view enables systems to detect and track potential intruders before they physically breach a perimeter. The M8 PoE+ provides a signifcantly smaller overall footprint than other PoE+ sensors and radars. Unlike traditional security camera technology, the M8 operates successfully in challenging weather environments as well as in the dark. Paired with Quanergy’s proprietary LiDAR perception software, QORTEX for Security™, the M8 can be used as a standalone solution, or as an integrated component of a larger security system.

“We built the M8 with Power over Ethernet to enable our security customers to implement a LiDAR-based security system as easily as they would a camera-based surveillance system,” said Dr. Louay Eldada, CEO of Quanergy. “Our LiDAR sensors lead the industry in price, performance, and reliability. With PoE+, our customers can easily harness the power of LiDAR to ensure the highest level of security and awareness around vulnerable perimeters, protecting critical infrastructure such as airports, national borders, subways, power plants, oil fields and prisons.”

In addition to offering its technology as a standalone security solution, Quanergy deploys its technology in partnership with public safety and security technology firms (system integrators or SI) such as Vision Logic, many of whom are already using Power over Ethernet to connect other surveillance tools, such as IP cameras. This new availability allows SIs to flexibly incorporate Quanergy’s LiDAR technology into existing security systems, reducing installation time and costs.

“Integrating LiDAR technology into our video surveillance and facial recognition systems enables us to offer an unparalleled level of security and awareness to our customers,” said John Walsh, co-founder of Vision Logic. Graham Conran, co-founder and CEO of Vision Logic added “With Power over Ethernet, we can more easily incorporate Quanergy’s industry leading LiDAR sensors into our public safety and security platforms, tailoring our solutions to each of our customers’ needs.”

The M8 with PoE+ will be on display at two leading security industry events. Quanergy will be exhibiting at GSX in Las Vegas, September 25-27, in booth #2885. At Security Essen in Germany, September 26-28, the sensor will be in both the Milestone Systems and Genetec booths in Hall 5. Genetec will be in booth #5G30 and Miletsone will be in booth #5F10. General availability of the M8 sensor with PoE+ is November 2018.

About Quanergy Systems, Inc.

Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is the leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification and tracking. Its sensors are disruptive in price, performance, reliability, size, weight and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com .

Contact:

Quanergy Systems, Inc. Ann Gargiulo, +1-408-245-9500 Director of Marketing Communications media@quanergy.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye